Drugs / Azirkitug
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05005403 | Nov 2021 → Jul 2027 expected | colorectal cancer, gastroesophageal cancer, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +3 | AbbVie | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azirkitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005403 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL6068092 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT05005403 ↗ |